Insmed Incorporated (NASDAQ: INSM) announces that members of the Company's executive management team will be presenting at the 13thAnnual Needham & Co. Healthcare Conference taking place from April 8 - 9, 2014 at the Westin Grand Central Hotel in New York City.
Will Lewis, President and CEO, will present a corporate overview on April 9th at 8:00 a.m. Eastern time. Mr. Lewis' presentation will be webcast live on the internet and can be accessed by visiting the Investor Relations section of the Company's website atwww.insmed.com. A replay of the webcast will be archived on the Insmed website for 90 days following the presentation.
Needham & Company to Host 13th Annual Healthcare Conference, April 8 and 9, 2014
High-Impact Forum for Biotechnology, Specialty Pharma, Medical Technology and Diagnostics Sectors
Needham & Company, LLC (Needham & Company) will host its 13th Annual Healthcare Conference at the Westin New York Grand Central Hotel on April 8 and 9, 2014. The Needham Healthcare Conference is considered to be one of the best venues for leading life science and medical technology companies and institutional investors.
This high-impact forum for institutional investors and venture capital firms will feature updates from senior management of approximately 115 public and private companies in the Biotechnology, Specialty Pharmaceutical, Medical Technology and Diagnostics sectors. The conference format features presentations as well as one-on-one meetings.
The conference is open to clients of Needham & Company by invitation only. For more information, please call (212) 371-8300
Sentiment: Strong Buy
Think about this. They clearly were added to the Needham conference very late in the process. They clearly have used their results to be added to the conference. I suspect we will hear that even more participants went "culture negative" over the past couple of weeks and that they reached the Primary endpoint goal a couple of weeks later than expected - but reached it nonetheless. They would not have worked their way into this conference if they did not have something they want to get out to investors. i doubt the FDA cares whether they hit the primary endpoint in 98 days instead of 84 days. And, per another post, the FDA recommends that patients stay on treatment for an entire year for NTM - even if it is "cured". This means that they get a full year of sales for each patient even though they were cured in 84 days, ie. a lot more revenue per patient than previously thought. This is a serious blockbuster product.
Sentiment: Strong Buy